Osaka University

Nippon Zoki Pharmaceutical Co., Ltd.

National Institute for Materials Science

Murata Manufacturing Co., Ltd.

Horiba, Ltd.

Aimedic Mmt Co., Ltd.

Hideki Yoshikawa

Hiroyuki Tanaka

Tsuyoshi Murase

Mitsuru Naiki

Hideki Mochizuki

Kousuke Baba

Toru Iwahashi

Tsutomu Sasaki

Mitsuhiro Ebara

Kiyoshi Okada

Koji Suzuki

Naoki Ohashi

Sakyo Hirose

Shintaro Komatani

Satoshi Hamaguchi

Sumito Ohzawa

Hiroki Fujisawa

Kenichi Obori

Tomonori Matsumoto

Hiromoto Nakazawa

Aurel-Mihai Vlaicu

Chieko Asamori

Takashi Kaito

Satoshi Sugimoto

Tomoko Deguchi

Ryota Chijimatsu

Kouji Suzuki

Yukihiko Yasui

Kazunori Shimomura

Norimasa Nakamura

Yu Moriguchi

To provide an artificial bone having a porous structure with an improved affinity to osteogenic cells, an artificial bone () includes: a base material () containing porous ceramics provided with mutually interconnected multiple pores (); a carbonaceous thin film () formed on an outer surface of the base material and wall surfaces () of the pores; and functional groups () including amino groups () provided on a surface and in an interior of the carbonaceous thin film.

Artificial bone and manufacturing method of artificial bone

An object is to provide a drug which is useful in treating a nervous system disease. A drug containing vitamin Bas an active ingredient according to the present invention has an M2 macrophage/microglia induction promoting effect, an M1 macrophage/microglia induction inhibiting effect, a nerve regeneration promoting effect, and the like and is very useful as a therapeutic agent for a nervous system disease, and particularly useful as a therapeutic agent for a central nervous system disease such as cerebral infarction, dementia, or spinal cord injury.

Therapeutic agent for nervous system disease

A sustained release sheet that includes a drug for treating nerve injury, wherein the sheet is applied to a nerve injury site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration without stimulating the nerves, even when the sheet is implanted in the periphery of the nerve injury site. Also provided is a production method for the sheet. This sustained drug release sheet for treating nerve injury is a sheet including a non-woven fabric that is formed from nanofibers each containing a drug such as vitamin B12 and a biocompatible polymer such as a biodegradable aliphatic polyester, and is implanted in the periphery of the nerve injury site to promote nerve regeneration.

Sustained drug release sheet for treating nerve injury

A method of treating a central nervous system disease, the method including administering an agent including a therapeutically effective amount of vitamin Bto a patient with a central nervous system disease to treat the central nervous system disease. This disclosure also relates to a method of promoting M2 macrophage/microglia induction, inhibiting M1 macrophage/microglia induction, and/or reducing the ratio of M1 macrophage/microglia to M2 macrophage/microglia in a patient in need thereof, the method including administering an agent including a therapeutically effective amount of vitamin Bto the patient to promote M2 macrophage/microglia induction, inhibit M1 macrophage/microglia induction, and/or reduce the ratio of M1 macrophage/microglia to M2 macrophage/microglia. This disclosure also relates to a pharmaceutical product including vitamin B.

Provided is a sustained release sheet that includes a drug for treating nerve injury, wherein the sheet is applied to a nerve injury site, can maintain a high concentration of the drug over a long period, and promotes nerve regeneration without stimulating the nerves, even when the sheet is implanted in the periphery of the nerve injury site. Also provided is a production method for the sheet. This sustained drug release sheet for treating nerve injury is a sheet comprising a non-woven fabric that is formed from nanofibers each containing a drug such as vitamin B12 and a biocompatible polymer such as a biodegradable aliphatic polyester, and is implanted in the periphery of the nerve injury site to promote nerve regeneration.

A Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like contain an extract from inflamed tissues inoculated with vaccinia virus. The extract from inflamed tissues inoculated with vaccinia virus promotes differentiation of Schwann cells and regeneration of a peripheral nerve. Therefore, a preparation containing the extract from inflamed tissues inoculated with vaccinia virus is useful as a Schwann cell differentiation promoting agent, a peripheral nerve regeneration promoting agent, or the like.

Schwann cell differentiation promoting agent and a peripheral nerve regeneration promoting agent

The object of the present invention is to provide a test method using a novel administration method of an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract. It has been demonstrated that by sustainedly administering an extract from inflamed tissues inoculated with vaccinia virus or a preparation containing the extract by using a continuous administration device according to the present invention, a comparable effect is exerted at a very low dose compared with conventional administration methods such as oral administration. Therefore, the present invention can provide a test method using animals requiring less burden on a researcher, a treatment of patient at a low dose, and the like.

Test method

A resistance switching device having a high resistance variation ratio, an excellent response characteristic, an excellent resistance memory characteristic (retention characteristics) and an excellent repeat resistance. The resistance switching device comprises an n-type oxide semiconductor and first and second electrodes which are disposed so as to interpose at least a part of the n-type oxide semiconductor therebetween wherein a Schottky junction which provides resistance variation/memory characteristics by the application of voltage having different polarities between the first and second electrodes is formed at an interface between the n-type oxide semiconductor and the first electrode; and the first electrode is positioned such that it is in contact with the n-type oxide semiconductor, and has a lower layer which is formed from Au oxide or a Pt oxide or Au or Pt containing oxygen having the thickness of 1-50 nm.

Resistance switching device and process for producing thereof

An X-ray convergence element and an X-ray irradiation device including the X-ray convergence element are provided. The X-ray convergence element can extend a working distance from an exit-side opening end thereof to a specimen, and can perform analysis of the specimen with rough surface, a fluorescent X-ray analysis, and a X-ray diffraction analysis, regardless of a size of the specimen. An X-ray blocking memberis provided with three supporting membersfor supporting the X-ray blocking member, which extend from an annular memberhaving approximately the same diameter as a diameter of an entrance-side opening end (outer diameter of a capillary) toward the center of the X-ray blocking memberto fix the annular memberto the capillary. The annular member, the supporting members, and the X-ray blocking memberare integrally formed of a metal that shields X-rays, such as tantalum, tungsten, or molybdenum. A dimension of the X-ray blocking memberin the axial direction (thickness) is set to be sufficient for blocking X-rays.

X-ray convergence element and X-ray irradiation device

Growing community of inventors

Suita, Japan

Hideki Yoshikawa